<DOC>
	<DOCNO>NCT00418626</DOCNO>
	<brief_summary>This study formal assessment impact hepatic function impairment pharmacokinetics nilotinib</brief_summary>
	<brief_title>Pharmacokinetics Nilotinib Subjects With Impaired Hepatic Function Healthy Subjects With Normal Hepatic Function</brief_title>
	<detailed_description />
	<criteria>1 . Healthy adult male ( 18 70 yr ) 2 . Body weight must â‰¥ 50 kg &lt; 120 kg , body mass index ( BMI ) &gt; 18 &lt; 35 . 3 . Laboratory parameter value within normal range 1 . Contraindication hypersensitivity receive nilotinib 2 . Smokers use tobacco product product contain nicotine 3 . A past medical history clinically significant Electrocardiogram abnormality history/family history long QTinterval syndrome . 4 . History fainting spell . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>nilotinib</keyword>
	<keyword>hepatic impairment</keyword>
	<keyword>Child-Pugh scale</keyword>
	<keyword>PK</keyword>
	<keyword>healthy , subject ( )</keyword>
	<keyword>Subjects impair hepatic function healthy subject</keyword>
</DOC>